Doctors caution that successful outcomes could depend on how early patients are referred to a specialist for advanced therapies.
Jane Racey Gleeson
Jane Racey Gleeson has been a member of the University of Michigan Frankel Cardiovascular Center’s communications team as a contributing writer for the past five years. She works with the team to produce targeted communications for a variety of Frankel CVC-related projects. Gleeson’s 30+ years in the technical communications field extends to custom publications, website development and integrated marketing for a variety of clients. She holds a bachelor’s degree in journalism from Oakland University in Rochester, Michigan.
One patient had no discomfort associated with a rare aneurysm on her jugular vein — until a rupture required immediate surgery.
Could a tiny device designed to avert stroke-provoking clots be a substitute for medication? The technology is an option for certain at-risk patients.
For those with a rare form of blood clots called CTEPH, a complex surgery is often the fix when medication fails. A U-M cardiac surgeon speaks about the procedure.